Outcomes of patients with Cholesterol crystal embolism treated by peritoneal dialysis: retrospective study from the RDPLF registry.





peritoneal dialysis, survival, outcome, cholesterol crystal embolism, renal failure


Cholesterol crystal embolisms disease (CED) is a systemic disease characterized by tissue ischemia and microinflammation related to occlusion of arterioles by microemboli from ulcerated atheromatous plaques. The kidney is one of the most affected organs, often requiring dialysis. Our study examines the outcomes of a cohort of patients with CED treated with peritoneal dialysis (PD). As anticoagulants can favor emboli, peritoneal dialysis may theoretically have an advantage.

From the database of the French Language Peritoneal Dialysis Registry (RDPLF), between January 1, 1995, and December 31, 2021, we selected patients treated with PD for >90 days and with an age >18 years. On the basis of the variables of patient autonomy, diabetes, BMI, modified Charlson index, age, sex, pre-PD treatment, causes of death, causes of transfer to hemodialysis, and peritonitis, three types of survival were estimated (patient, technical, and composite). After adjustment by propensity scores and taking into account competitive risks, 2 groups of patients were constituted on the basis of baseline nephropathy: emboli group vs. control group.

Patient survival and strict technical survival are not associated with the type of nephropathy (CED versus others). Composite technical survival (uncensored for deaths and transfers to hemodialysis) was only associated with cholesterol emboli nephropathy in the multivariate analysis adjusted for diabetes, autonomy, and age of the patient at the start of the dialysis treatment (p=0.011; 95% CI [0.736 [0.581-0.931]]).

Our study from the RDPLF database shows no difference in technical and patient survival in a cohort of patients with CED vs. a control group. It also confirms that PD may represent an adequate choice in this pathology.


Mulay SR, Anders HJ. Crystallopathies. N Engl J Med. 2016;374(25):2465-2476.

Mulay SR, Anders HJ. Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat Rev Nephrol. 2017;13(4):226-240

Shi C, Kim T, Steiger S, et al. Crystal Clots as Therapeutic Target in Cholesterol Crystal Embolism. Circ Res. 2020;126(8):e37-e52.

Ozkok A. Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag. 2019;15:209-220.

Denis Le Seve J, Gourraud Vercel C, Connault J, Artifoni M. État des lieux de la maladie des emboles de cholestérol [Update on cholesterol crystal embolism]. Rev Med Interne. 2020;41(4):250-257.

Tanaka H, Yamana H, Matsui H, Fushimi K, Yasunaga H. Proportion and risk factors of cholesterol crystal embolization after cardiovascular procedures: a retrospective national database study. Heart Vessels. 2020;35(9):1250-1255.

Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: A recognizable cause of renal disease. Am J Kidney Dis. 2000;36(6):1089-1109

Meyrier A. Cholesterol crystal embolism: diagnosis and treatment. Kidney Int. 2006;69(8):1308-1312.

Scolari F, Ravani P, Gaggi R, et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation. 2007;116(3):298-304.

Scolari F, Ravani P. Atheroembolic renal disease. Lancet. 2010;375(9726):1650-1660.

Li X, Bayliss G, Zhuang S. Cholesterol Crystal Embolism and Chronic Kidney Disease. Int J Mol Sci. 2017;18(6):1120.

Piccoli GB, Fenoglio R, Colla L, et al. Cholesterol crystal embolism syndrome in dialysis patients: an emerging clinical diagnosis?. Blood Purif. 2006;24(5-6):433-438.

Matsui K, Mochida Y, Ishioka K, et al. A case of enteric peritonitis in a patient with stage 5 kidney disease due to cholesterol crystal embolization. Perit Dial Int. 2020;40(2):220-221

González AP, Juega J, Vazquez C, et al. Late Onset of Cholesterol Embolism Leading to Graft Failure After Renal Transplantation: Report of Two Cases. Transplant Proc. 2015;47(8):2361-2363.

Verger C, Ryckelynck JP, Duman M, Veniez G, Lobbedez T, Boulanger E, Moranne O. French peritoneal dialysis registry (RDPLF): outline and main results. Kidney Int Suppl. 2006 Nov;(103):S12-20. doi: 10.1038/sj.ki.5001911. Erratum in: Kidney Int Suppl. 2007 Jan;71(1):87. Fabre, E [added].

Verger C, Fabre E, Veniez G, Padernoz MC. Synthetic 2018 data report of the French Language Peritoneal Dialysis and Home Hemodialysis Registry (RDPLF). Bull Dial Domic [Internet]. 2019Apr.10 [cited 2022Feb.25];2(1):1-10. Available from: https://doi.org/10.25796/bdd.v2i1.19093

White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011;30). 377-399

Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996 Aug;17(4):343-6

. Fine J and Gray R-J. A Proportional Hazards Model for the Subdistribution of a Competing Risk, Journal of the American Statistical Association, Vol. 94, No. 446 (Jun., 1999), pp. 496-509

Gillerot G, Sempoux C, Pirson Y, Devuyst O. Which type of dialysis in patients with cholesterol crystal embolism?. Nephrol Dial Transplant. 2002;17(1):156-158.

Ravani P, Gaggi R, Rollino C, et al. Lack of association between dialysis modality and outcomes in atheroembolic renal disease. Clin J Am Soc Nephrol. 2010;5(3):454-459.

Indications et non-indications de la dialyse péritonéale chronique chez l’adulte RECOMMANDATION DE BONNE PRATIQUE - Octobre 2008 HAS. [Internet, cited 2022Feb.25]; available from




How to Cite

Testa A, Chamorey E, Lavainne F, Verger C. Outcomes of patients with Cholesterol crystal embolism treated by peritoneal dialysis: retrospective study from the RDPLF registry. . Bull Dial Domic [Internet]. 2022 Apr. 6 [cited 2023 Mar. 27];5(1):1-11. Available from: https://www.bdd.rdplf.org/index.php/bdd/article/view/65303